Ref No: DGS 032
24 May 2018

Dear

Freedom of Information Request

Further to your FOI request dated 21 May 2018 the information is below

- **How much of a focus is this document for your CCG and how much resource will you be assigning to dealing with it?**
  - Answer on a scale of 1-5, 5 being maximum effort assigned to it and then why specifically?

  3. NHS Dartford Gravesham and Swanley Clinical Commissioning Group (CCG) has been focusing on reducing OTC prescribing over the last year and will continue to remain focused on this area with the support of this document. The NHSE document provides greater backing for the advice we have offered over the last year.

  The CCG has associated some QIPP savings to this prescribing.

- **Which of the approx. 36 conditions/diseases will be a focus for your CCG to implement change.**
  - Please list the conditions which are the main or primary focus

  The CCG focuses on OTC products as a whole and not specifically on any particular condition.

  The CCG asks practices to use the document as a guide and de-prescribe as and when they feel appropriate based on their clinical judgement.
Please list the top five conditions/diseases/areas that your CCG will want to work in this document

As mentioned above, the CCG focuses on all OTC products as a whole however areas where we prescribe the majority are as follows:

- Mild to Moderate Hay fever/Allergic Rhinitis
- Minor conditions associated with pain, discomfort and/fever. (e.g. aches and sprains, headache, period pain, back pain
- Mild Dry Skin/Sunburn
- Dry Eyes/Sore tired Eyes

• For the conditions that are not a focus for you, when will they be?
  o When do you expect to complete working through all 36 conditions, or do you? What month and what year specifically?

There is no fixed plan or completion date for working through the 36 conditions and efforts to reduce spend on OTC products will be on a continuous, long term basis.

• When you are looking to implement change on this guidance document for some conditions or all, what procedures and systems will you use and how?

  - Dependant on the area we may use various different methods; for some areas the CCG will produce guidelines and for others there may be practice based audits to identify patients routinely prescribed OTC medication, but there is no fixed plan for this as yet

  - Also to continue to engage with prescribers and the public, making them aware of the new guidance and encouraging behavioural change

• For things like Optimise Rx, what will the instruction be on this system?

  The CCG does not use Optimise Rx.

• For the area of dry/sore tired eyes in this document, will secondary care involvement be required before looking to make any of these changes?

  Secondary care will be involved where it is necessary

Please note, that the supply of information in response to a FOI request does not confer an automatic right to re-use the information. Under UK copyright law you can use any information supplied for the purposes of private study and non-commercial research without requiring permission. Similarly, information supplied can also be re-used for the purposes of news reporting. An exception to this is photographs.

If you are unhappy with the service that you have received in relation to your request and wish to make a complaint or request a review of our decision you should write to
Complaints. NHS Dartford Gravesham and Swanley Clinical Commissioning Group
2nd Floor Gravesham Civic Centre Gravesend Kent DA12 1AU or email at
dgscrg.complaints@nhs.net

If you are not content with the outcome of your complaint or review, you may apply to
the Information Commissioner for a decision. Generally the ICO cannot make a
decision unless you have exhausted the complaints procedure provided by the
Clinical Commissioning Group. The Information Commissioner can be contacted at:

| Information Commissioners Office, |
| Wycliffe House, |
| Water Lane, |
| Wilmslow, |
| Cheshire |
| SK9 5AF |
| Telephone: 08456 306060 or 01625 54 57 45 |
| www.ico.gov.uk |

Please remember to quote the reference number above in any future
communications.